Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Capecitabine vs Capecitabine for Adjuvant Biliary Carcinoma
NCT03609489Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Sep 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in biliary tract cancer (BTC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03609489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609489.